Zentiva Completes Voluntary Public Purchase Offer for APONTIS PHARMA AG

RedHill Biopharma Divests Talicia to an Apotex Subsidiary for $18M Upfront Plus Milestones

August 31, 2026

Pharmaceuticals

RedHill Biopharma divested its 70% interest in the Talicia business to a subsidiary of Apotex Health for $18 million upfront cash, plus up to $35 million in worldwide net sales milestone payments. The company said proceeds will strengthen liquidity and fund the next stage of RedHill’s gastrointestinal commercial expansion, including scaling its GI franchise and pursuing new high-value FDA-approved opportunities.

Qvantel Acquires Optiva Inc.

December 31, 2025

Software

Qvantel Oy completed its acquisition of Optiva Inc. via a statutory plan of arrangement, acquiring all issued and outstanding common shares of Optiva. The transaction paid Optiva shareholders C$0.25 per common share, cancelled Optiva's US$108.6 million PIK notes with consideration to noteholders (including purchaser shares, purchaser-issued senior secured notes and warrants), and will result in Optiva being dissolved and delisted from the Toronto Stock Exchange. The combined company expands Qvantel's telecom monetization and digital operations portfolio and supports more than 70 operators with a global workforce exceeding 1,000 professionals.

GTCR Completes Acquisition of Zentiva From Advent to Expand European Generics Platform

September 11, 2025

Pharmaceuticals

GTCR has completed its previously announced acquisition of Zentiva, a leading European generics pharmaceutical company, from Advent. The deal expands GTCR’s European generics healthcare platform and is intended to drive growth through continued investment in product development, portfolio breadth, and geographic reach.

CapVest Acquires Majority Stake in STADA Arzneimittel

September 1, 2025

Healthcare Services

CapVest Partners LLP has completed its acquisition of a majority stake in STADA Arzneimittel AG, a global healthcare and pharmaceuticals company focused on consumer healthcare, generics, and specialty pharmaceuticals. CapVest and STADA plan to accelerate STADA’s global growth through both organic initiatives and strategic acquisitions.

Innoviva Acquires Entasis Therapeutics

May 23, 2022

Biotechnology

Innoviva agreed to acquire the remaining shares of Entasis Therapeutics it did not already own for $2.20 per share in cash, valuing Entasis equity at about $113 million on a fully diluted basis. Innoviva completed the acquisition in July 2022, making Entasis a wholly owned subsidiary.

AptarGroup Completes Acquisition of Majority Stake in Voluntis (Theraxium Digital Therapeutics)

September 2, 2021

Healthcare Services

AptarGroup, Inc. entered into exclusive negotiations and subsequently completed the acquisition of a majority stake (approximately 64.6%) in Voluntis, a digital therapeutics company. The transaction was followed by a mandatory cash tender offer to acquire Voluntis’ remaining shares at €8.70 per share, with a potential squeeze-out if regulatory conditions are met.